Japan's SBC Medical Q2 revenue beats on AI-powered support expansion

SBC Medical group

13/08/2026 11:41

Overview
Japan medical services group's fiscal Q2 revenue rose 13%, beating analyst expectations
Net income attributable to SBC Medical surged 335% yr/yr, with basic EPS up 400%
Earnings growth driven by AI-enabled service enhancements and successful fee increases

Outlook
Company expects annual service fees to rise by about $15 mln if initiatives are realized
SBC Medical plans to accelerate global growth via U.S. and ASEAN expansion
Company to deepen multi-brand strategy in aesthetic dermatology and expand non-aesthetic business

Result Drivers
AI-ENABLED SERVICE ENHANCEMENTS - Co said expansion of AI-powered support capabilities enabled successful fee increases and improved clinic operations
FEE INCREASES - Co said fee revisions for call center services and expanded support for affiliated clinics drove higher service fees
CLINIC NETWORK EXPANSION - Co said number of locations rose by 34 yr/yr to 287, with patient visits up 10% yr/yr

Company press release: ID:nBw43bHcFa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$49 mln
$45.45 mln (5 Analysts)
Q2 EPS
 
$0.10
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for SBC Medical Group Holdings Inc is $8.50, about 165.6% above its August 12 closing price of $3.20
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Aug 12 - Singapore's Beverly JCG half-year revenue falls 32% on weaker aesthetic medical
Aug 12 - Journey Medical Q2 revenue rises 23%, slightly beats estimates
Aug 13 - China's JD Health interim revenue rises on user growth, product expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)